uniQure (NASDAQ:QURE) Shares Gap Up – Should You Buy?

uniQure N.V. (NASDAQ:QURE) gapped up prior to trading on Thursday. The stock had previously closed at $20.97, but opened at $21.94. uniQure shares last traded at $21.8710, with a volume of 256,843 shares trading hands.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Wells Fargo & Company restated an “overweight” rating and set a $75.00 price target on shares of uniQure in a report on Tuesday, September 29th. HC Wainwright reaffirmed a “buy” rating on shares of uniQure in a research note on Tuesday, September 29th. The Goldman Sachs Group decreased their price objective on shares of uniQure from $46.00 to $31.00 and set a “neutral” rating for the company in a report on Wednesday, September 30th. Weiss Ratings raised shares of uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. Finally, UBS Group set a $48.00 target price on shares of uniQure in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $53.25.

uniQure Stock Up 3.9%

The firm has a 50-day moving average of $40.21 and a two-hundred day moving average of $33.83. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -5.43 and a beta of 1.06. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%. The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. During the same period in the prior year, the firm earned ($0.69) earnings per share. As a group, sell-side analysts predict that uniQure N.V. will post -3.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On uniQure

Large investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new stake in uniQure in the 2nd quarter valued at $15,254. IFP Advisors Inc grew its position in uniQure by 39.8% in the 2nd quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 791 shares during the last quarter. Arizona State Retirement System grew its position in uniQure by 17.7% in the 2nd quarter. Arizona State Retirement System now owns 12,940 shares of the biotechnology company’s stock worth $596,000 after purchasing an additional 1,942 shares during the last quarter. Rangeley Capital LLC increased its holdings in shares of uniQure by 52.9% during the 1st quarter. Rangeley Capital LLC now owns 13,000 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 4,500 shares during the period. Finally, Fulton Bank N.A. bought a new position in shares of uniQure during the 2nd quarter worth about $220,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.

uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.